Michael J. Mauro, M.D.

"We have seen a revolution in the way we treat chronic myelogenous leukemia (CML) with the development of Gleevec and other targeted therapies. I see my mission at OHSU as continuing the work done over the last decade in CML with an eye towards tailoring therapy for every patient, working for the best response with the use of newer treatments, minimizing side effects and risks and getting closer to a cure. Nothing brings me more joy than to erase confusion and fear about disease and replace it with knowledge and hope."

Biography

Dr. Mauro mainly sees patients with chronic myelogenous leukemia and myeloproliferative diseases. He has done extensive research at OHSU over the last decade into these conditions and how to treat them. His passion is working with patients in difficult situations, including those who are having side effects from treatment or whose disease is not responding well to treatment. He helps patients make crucial decisions about changes in treatment or alternative options such as stem cell transplants. He also has a passion for bringing new treatments to patients through clinical trials. Dr. Mauro prides himself on carefully explaining blood diseases, empowering patients to participate in decision-making and monitoring their progress. He makes sure patients understand every option available in their situation, and which might work best for their disease, depending on results and progress and the most current treatment options to those living with CML and related conditions.

Education

• Degree:
  M.D., Dartmouth Medical School
  
• Residency:
  Cornell University Medical Center, 1994-1997
• Fellowship:
  Hematology-Oncology, Weill Medical College of Cornell University - New York Presbyterian Hospital, 2000
• Certification:
  American Board of Internal Medicine (Medicine), 1997 American Board of Internal Medicine (Hematology), 2000